Generic drugs represent approximately 90% of prescriptions in the United States, largely due to their cost-effectiveness. However, the reliability of these medications has come under scrutiny, with over 60% of shortages linked to quality issues, as reported by the Food and Drug Administration (FDA). Many generic manufacturers, particularly those based in India, have faced citations for manufacturing violations that have resulted in product recalls and, in some cases, bans on imports to the U.S.
In light of these challenges, Kevin Schulman, a professor at Stanford University and deputy director of the Clinical Excellence Research Center, suggests a potential pathway to improve quality assurance. Schulman, who has collaborated with Valisure, an independent lab known for identifying impurities in pharmaceuticals, advocates for the FDA to promote testing by independent, accredited laboratories. This approach could enhance the credibility of generic drugs and restore consumer confidence.
In our recent conversation, Schulman elaborated on his vision for a more reliable generic drug supply chain. His insights could pave the way for regulatory changes that prioritize quality and safety in the pharmaceutical industry.
Continue to STAT+ to read the full story…
Get started today with Solo access →
